Webinar

Is Data Exclusivity Justified? Evidence on the Impacts on Innovation and Access to Medicines

Reed Beall, Mayra Vásquez, Miguel E Cortés G.

26 September 2019

Q&A Session with the Participants

16:03:53
From Marcela Vieira: Please send questions here to all panelists and attendees.

16:42:15
From Suerie Moon: Question for Reed Beall: What was the evidence for a 12-year period of DE in the US?

16:49:57
From Suerie Moon: Question for Mayra/Miguel: if R&D cost was a justification for granting of data exclusivity, was Colombian govt able or willing to require disclosure of R&D costs as a condition of applying for DE?

16:54:05
From Suerie Moon: 2nd question for Reed: given your understanding of impact of DE on innovation, what do you think would have been the impact on innovation of a shorter or zero-year period of DE in Colombia?

16:58:40
From Fernanda Steiner Perin to all panelists: question for all panelist: do you think that molecules developed with public funds don't should have DE?

16:58:52
From Juliana Veras to all panelists: Do we know if there is any pressure from intermediaries (economic actors) such as 23andMe (google) pressuring on the debate about data exclusivity and higher patent periods for biological new products ?

16:59:48
From Ujjwal Kumar to all panelists: is exclusively the only way to compensate innovators? can there be any cost sharing model where subsequent applicants share cost of developing the data?

17:01:14
From Fernanda Steiner Perin: question for all panelists: do you think that molecules developed with public funds should not have DE?

17:02:31
From Rhiannon Osborne to all panelists: What incentives and policies other than decreasing DE do you think could be done to increase the ability of competitors to enter the market for biosimilars? E.g. prize funding, R+D public funding. Do you think any of these will be effective without tackling DE?

17:03:30
From Ujjwal Kumar to all panelists: India which doesn't have a data exclusively and still trips compliant, argues that the extension of patent period from 14 years to 20 years in trips agreement compensate for the drug development time to bring it to market. Your views?

17:09:05
From Suerie Moon: In some countries patent laws have public interest/health safeguards but DE does not (e.g. no equivalent of compulsory license for DE). What is the situation in Colombia, Canada, or other countries the speakers are familiar with? Should there be such safeguards?

17:13:47
From Manuel Martin to all panelists: I think he also mentioned the Tobin tax to finance these models.

17:14:40
From Alma De León to all panelists: The Universities also do R&D

17:16:14
From Alma De León to all panelists: What about the medicines and new model for investment without exclusivity

17:16:31
From Vitor Ido to all panelists: thank you all!

17:16:33
From Ujjwal Kumar to all panelists: thank you.

17:16:35
From Suerie Moon: Thank you, everyone!

17:16:38
From Jaume Vidal: Excellent. Many thanks.